Antimicrobial activity of different Lactobacillus species against multi-drug resistant clinical isolates of Pseudomonas aeruginosa

Iranian Journal of Microbiology

Volumn 3, Issue 1, 2011, Pages 21-25

  Jamalifar, H ^a   Rahimi, H R ^a   Samadi, N ^a   Shaverdi, A R ^a   Sharifian, Z ^b   Hosseini, F ^a   Eslahi, H ^a   Fazeli, M R ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Department of Drug Regulatory Affairs   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti pseudomonal activity; Lactobacillus species; Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL PRACTICE; HUMAN; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS REUTERI; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SCREENING TEST;

LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS REUTERI; PSEUDOMONAS AERUGINOSA;

EID: 80051479235     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, et al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997; 28: 211-219.
2. Jarvis WR, Martone WJ. Predominant pathogens inhospital infections. J Antimicrob Chemother 1992; 29: 19-24.
3. Vosahlikova S, Drevinek P, Cinek O, Pohunek P, Maixnerova M, Urbaskova P, et al. High genotypic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in the Czech Republic. Res in Microbiol 2007; 158: 324-329.
4. Brook I. Otitis media: microbiology and management. J Otolaryngol 1994; 23: 269-275.
5. Lyczak, JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2000; 2: 1051-1060.
6. Burgess DS. Use of pharmacokinetics and pharma-codynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 2: S99-104.
7. Paul R. Rhomberg, Ronald N. Jones, Helio S. Sade. Results from the meropenem yearly susceptibility test information collection (MYSTIC) programme: report of the 2001 data from 15 United States medical centers. Int J Antimicrob Agents 2004; 23: 52-59.
8. Patzer JA, Dzieṙzanowska D. Increase of imipenemresistance among Pseudomonas aeruginosa isolates from a Polish pediatric hospital (1993-2002). Int J Antimicrob Agents 2007; 29: 153-158.
9. Gordon D, Macrae J, Wheater DM. A lactobacilluspreparation for use with antibiotics. Lancet 1957; 272: 899-901.
10. Vandenbergh PA. Lactic acid bacteria, their metabolicproducts and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221-238.
11. Carson CF, Riley TV. Non-antibiotic therapies for infecti-ous diseases. Commun Dis Intell 2003; 27: 143-146.
12. Gibbs PA. Novel uses for lactic acid fermentation infood preservation. J Appl Bacteriol Symp Suppl 1987; 63: 51S-58S.
13. Perry JD, Laine L, Hughes S, Nicholson A, Galloway A, Gould FK. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother 2008; 61: 1057-61.
14. Pinto AL, Fernandes M, Pinto C, Albano H, Castilho F, Teixeira P, et al. Characterization of anti-Listeria bacteriocins isolated from shellfish: potential antimicrobials to control non-fermented seafood. Int J Food Microbiol 2009; 129: 50-8.
15. Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y. Detection of extended-spectrum β-Lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agts Chemother 2006; 50: 2990-2995.
16. Shannon KP and French GL. Increasing resistanceto antimicrobial agents of Gram-negative organisms isolated at a London teaching hospital, 1995-2000. J Antimicrob Chemother 2004; 53: 818-825.
17. Johann DDP, Barbara LC, Daniel BG, Kevin BL, Sameer E, Deirdre LC. Molecular epidemiology of metallo-ß-lactamase-producing Pseudomonas aeruginosa in the Calgary health region: Emergence of VIM-2-producing isolates. J Clin Microbiol 2007; 45: 294-298.
18. Victor Lorian. Antibiotics in laboratory medicine. 5rded. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 12-85.
19. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-291.
20. Engel LS, Callegan MC, Hill JM, Richard J. Bioassaysfor quantitating ciprofloxacin and tobramycin in aque-ous humor. J Ocul Pharmacol 1993; 9: 311-320.
21. Nicasio AM, Kuti JL, Nicolau DP. The current stateof multidrug-resistant Gram-negative bacilli in North America. Pharmacotherapy 2008; 28: 235-249.
22. Souli M, Galani I, Giamarellou H. Emergence ofextensively drug resistant and pan-drug-resistant Gram-negative bacilli in Europe. Euro surveill 2008; 13: 1-11.
23. Siegel RE. Emerging Gram-negative antibioticresistance: daunting challenges, declining sensitivity, and dire consequences. Respir Care 2008; 53: 471-479.
24. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical andeconomic impact of common multidrug resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008; 52: 813-821.
25. Slama TG. Gram-negative antibiotic resistance: there isa price to pay. Crit Care 2008; 12: 233-239.
26. Chopra I, Schofield C, Everett M, O'Neill A, Miller K, Wilcox M, et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consens-us statement. Lancet Infect Dis 2008; 8:133-139.
27. Antonio MAD, Hawes SE, Hillier SL. The identificationof vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 1999; 180: 1950-1956.
28. Redondo-López V, Cook RL, Sobel JD. Emerging roleof lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990; 12: 856-872.
29. Servin AL. Antagonistic activities of lactobacilli andbifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004; 28: 405-440.
30. Mcfarland LV. Normal flora: diversity and functions. Microb Ecol Health Dis. 2000; 12: 193-207.
31. Reid G, Burton J. Use of lactobacillus to prevent Infection by pathogenic bacteria. Microbes infection. 2002; 4: 319-24.
32. Gill H. S, Rutherfurd K. J, Cross M. L, Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019 Am J Clin Nutr 2001; 74: 833-839.
33. Osset J, Bartolomé RM, García E, Andreu A. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001; 183: 485-491.
34. Baerheim A, Larsen E, Digranes A. Vaginal applicationof lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care 1994; 12: 239-43.
35. Reid G, Millsap K, Bruce AW. Implantation of Lactobacillus casei var. rhamnosus into vagina. Lancet 1994; 344: 1229.
36. Bruce AW, Reid G. Intravaginal instillation oflactobacilli for prevention of recurrent urinary tract infections. Can J Microbiol 1988; 34: 339-43.
37. Reid G, Bruce AW, Taylor M. Influence of three-day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infection. Clin Ther 1992; 14: 11-16.